AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
- AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago.
- 01/08/2025
|
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa.
- 01/08/2025
|
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30.
- 01/06/2025
|
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Confer.
- 01/06/2025
|
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte.
- 12/19/2024
|
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
- AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.
- 12/10/2024
|
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
- AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 12/10/2024
|
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation follow.
- 12/09/2024
|
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
- The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/01/2024
|
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
- ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
- 10/29/2024
|
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
- AngioDynamics announces the receipt of CPT Category I code for IRE technology.
- 10/23/2024
|
AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 10/08/2024
|
AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise
- AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.
- 10/04/2024
|
Here's Why You Should Add AngioDynamics Stock to Your Portfolio
- ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.
- 10/03/2024
|
Why AngioDynamics Stock Is Crashing Today
- Investors didn't like the medical technology company's fiscal 2025 Q1 update.
- 10/03/2024
|
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
- U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.
- 10/03/2024
|
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
- AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago.
- 10/03/2024
|
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million.
- 10/03/2024
|
Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
- AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
- 10/03/2024
|
New Strong Buy Stocks for September 30th
- MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
- 09/30/2024
|
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
- AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
- 09/23/2024
|
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety and long term functional outcomes of percutaneous mechanical aspiration thrombectomy for Treatment of Acut.
- 09/19/2024
|
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to.
- 09/19/2024
|
New Strong Buy Stocks for September 13th
- ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
- 09/13/2024
|
New Strong Buy Stocks for September 9th
- DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.
- 09/09/2024
|
AngioDynamics Stock Falls Despite CE Mark for Auryon System
- ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
- 09/04/2024
|
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why
- AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/27/2024
|
Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?
- The mean of analysts' price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 08/14/2024
|
Should You Buy AngioDynamics (ANGO) After Golden Cross?
- From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
- 08/01/2024
|
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/29/2024
|
New Strong Buy Stocks for July 29th
- KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.
- 07/29/2024
|
AngioDynamics: Lumpy Progress Is Still Progress
- AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife generated double-digit year-over-year growth, while AlphaVac bounced back strongly on a sequential basis, and gross margin improved more than three points. Execution remains the key here, as Auryon, AlphaVac, and NanoKnife all have legitimate growth potential, but significant competition as well.
- 07/17/2024
|
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
- AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
- 07/17/2024
|
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
- Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16.
- 07/16/2024
|
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
- AngioDynamics (ANGO) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to earnings of $0.02 per share a year ago.
- 07/16/2024
|
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval
- AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
- 05/22/2024
|
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE). “The CE Mark represents a major.
- 05/21/2024
|
AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hos.
- 05/06/2024
|
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
- AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful.
- 04/09/2024
|
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
- Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
- 04/05/2024
|
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
- AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
- 04/05/2024
|
AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript
- AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mode.
- 04/04/2024
|
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its Uniblate and Starburst RadioFrequency products, as well as its Syntrax support catheter products, to further streamline its product portfolio GAAP As Reported Pro Forma* Net Sales: $75.2 million $66.0 million Growth: N/A 8.0% Gross Margin 47.7% 51.1% GAAP Loss per Sh.
- 04/04/2024
|
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE. PE affect.
- 04/04/2024
|
AngioDynamics (ANGO) Settles Patent Litigations With BD
- AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
- 04/02/2024
|
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. Under the terms of the settlement, BD.
- 04/01/2024
|
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
- AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/28/2024
|
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to.
- 03/19/2024
|
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
- In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.
- 03/15/2024
|
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
- In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.
- 03/08/2024
|
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healt.
- 03/06/2024
|
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
- Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.
- 03/04/2024
|
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
- In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.
- 02/22/2024
|
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
- AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.
- 02/16/2024
|
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
- AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.
- 02/15/2024
|
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
- The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.
- 02/09/2024
|
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
- AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.
- 01/25/2024
|
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
- AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.
- 01/08/2024
|
Why AngioDynamics Stock Got Destroyed Today
- The adjusted losses that the medical device maker reported for its fiscal Q2 weren't as bad as expected, but its sales weren't as good as expected. The Nanoknife-maker has lost money for five straight years.
- 01/05/2024
|
AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates
- AngioDynamics (ANGO) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.
- 01/05/2024
|
AngioDynamics stock dives after sales miss, lowered full-year outlook
- Shares of AngioDynamics Inc. ANGO, +0.26% plummeted 16.8% in premarket trading, after the medical devices company widened its full-year loss forecast and announced a restructuring of its manufacturing footprint. Net losses for the fiscal second quarter to Nov. 30 widened to $29.05 million, or 72 cents a share, from $8.49 million, or 21 cents a share, in the year-ago period.
- 01/05/2024
|
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 a.
- 12/21/2023
|
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note
- AngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day.
- 12/11/2023
|
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same.
- 12/07/2023
|
AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to Know
- AngioDynamics (ANGO) closed the most recent trading day at $6.77, moving -1.31% from the previous trading session.
- 12/04/2023
|
AngioDynamics (ANGO) Stock Slides as Market Rises: Facts to Know Before You Trade
- In the most recent trading session, AngioDynamics (ANGO) closed at $6.74, indicating a -0.15% shift from the previous trading day.
- 11/28/2023
|
AngioDynamics (ANGO) Outperforms Broader Market: What You Need to Know
- AngioDynamics (ANGO) closed the most recent trading day at $6.85, moving +1.33% from the previous trading session.
- 11/22/2023
|
AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note
- In the latest trading session, AngioDynamics (ANGO) closed at $6.86, marking a -1.15% move from the previous day.
- 11/16/2023
|
AngioDynamics (ANGO) Advances But Underperforms Market: Key Facts
- In the closing of the recent trading day, AngioDynamics (ANGO) stood at $6.21, denoting a +0.65% change from the preceding trading day.
- 11/10/2023
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
- 10/06/2023
|
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
- AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.
- 10/05/2023
|
Why Angiodynamics Stock Sank Today
- The medical device and technology specialist unveiled its latest set of quarterly results. Its bottom line was in the red and only marginally beat estimates.
- 10/04/2023
|
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
- AngioDynamics (ANGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.06 per share a year ago.
- 10/04/2023
|
Why AngioDynamics Stock Popped on Monday
- An investment bank initiated coverage of the stock with a buy rating this morning. The banker believes AngioDynamics stock could nearly triple over the next year.
- 09/25/2023
|
AngioDynamics: Enormous Effort Required In Fiscal '24 To Reverse The Equity Picture
- AngioDynamics, Inc. posted mixed results in its FY'23 reports, with strong growth in its Med Tech division. The company's focus going forward will be on its Med Tech segment, which has shown high growth and higher margins. It's the economic performance that matters here, with investment and profitability trends drawn into question.
- 09/17/2023
|
AngioDynamics (ANGO) Flat As Market Sinks: What You Should Know
- AngioDynamics (ANGO) closed at $8.58 in the latest trading session, marking no change from the prior day.
- 08/17/2023
|
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
- The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
- 08/16/2023
|
Should Growth Investors Buy This Revolutionary Small-Cap Stock?
- AngioDynamics' net sales and earnings rose in its fiscal fourth quarter. The company's future product launches could generate growth.
- 07/25/2023
|
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
- AngioDynamics (ANGO) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.01 per share a year ago.
- 07/12/2023
|
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
- AngioDynamics (ANGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/05/2023
|
AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the fourth quarter and fiscal year 2023 before the market open on Wednesday, July 12, 2023. The Company's management will host a conference call at 8:00 a.m. ET the sam.
- 06/20/2023
|
Why Shares of AngioDynamics Rose Friday
- AngioDynamics makes vascular and oncology-related medical devices. AngioDynamics netted $100 million in its assets sale.
- 06/09/2023
|
New Strong Sell Stocks for May 18th
- ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.
- 05/18/2023
|
Is the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?
- Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.
- 05/15/2023
|
Sell These 4 Toxic Stocks to Prevent Portfolio Losses
- The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.
- 05/15/2023
|
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 04/26/2023
|
4 Toxic Stocks That Are Detrimental to Your Portfolio's Health
- Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
- 04/14/2023
|
Wall Street Thinks This Small-Cap Stock Can Double in Value
- AngioDynamics' sales rose in its latest quarter. The medical device maker's financial health is solid.
- 04/04/2023
|
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
- AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
- 03/31/2023
|
AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2023
|
Is This Under-the-Radar Growth Stock a Buy?
- This company is a small player in the steadily growing medtech industry.
- 01/19/2023
|
AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?
- 01/05/2023
|
Wall Street Thinks This Obscure Growth Stock Could Soar 92% in 2023
- As COVID-19 headwinds fade, AngioDynamics' business could rebound.
- 12/30/2022
|
AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023
- LATHAM, N.Y.--( BUSINESS WIRE )--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open on Thursday, January 5, 2023. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results.
- 12/15/2022
|
AngioDynamics to Present at the Piper Sandler Healthcare Conference
- LATHAM, N.Y.--( BUSINESS WIRE )--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on Wednesday, November 30, 2022.
- 11/17/2022
|
Here's Why This Hidden Growth Stock Is a Buy
- This medical device company may not be a household name, but it could be an up-and-comer.
- 10/21/2022
|
4 Toxic Stocks That May Stress You Out Amid Market Turmoil
- Just like identifying promising stocks, detecting toxic stocks and dumping them at the right time are crucial to safeguarding one's portfolio from big losses.
- 10/13/2022
|
AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates
- AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.
- 10/10/2022
|
AngioDynamics, Inc.'s (ANGO) Q1 2023 Earnings Call Transcript
- AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2023 Earnings Conference Call October 6, 2022 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - Executive Vice President and CFO Conference Call Participants Steven Lichtman - Oppenheimer & Company Matthew Mishan - KeyBanc Capital Markets Bill Plovanic - Canaccord Genuity Operator Good morning. And welcome to the AngioDynamics' Fiscal Year 2023 First Quarter Earnings Call.
- 10/06/2022
|
Why AngioDynamics Stock Just Crashed 12%
- Is AngioDynamics' earnings miss a buying opportunity?
- 10/06/2022
|
AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 1.99%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/06/2022
|
AngioDynamics to Report Fiscal 2023 First Quarter Financial Results on October 6, 2022
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market open on Thursday, October 6, 2022. The Company's management will host a conference call at 8:00 a.m. ET the sam
- 09/08/2022
|
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
- AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
- 08/31/2022
|
Why Is AngioDynamics (ANGO) Up 15.4% Since Last Earnings Report?
- AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
- 08/11/2022
|
Should You Buy This Under-the-Radar Growth Stock?
- Like the Nasdaq Composite, this little-known medical device stock has been beaten down in 2022.
- 07/29/2022
|
AngioDynamics: Growth Is Encouraging, But Margins Still A Work In Progress
- AngioDynamics posted better sales growth in FQ4'22 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly. The company is building a sustainable core growth story, with multiple opportunities to gain share and grow addressable markets in thrombectomy, atherectomy, and cancer.
- 07/13/2022
|
Raymond James Cuts Price Target On AngioDynamics
- Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes ANGO is undervalued given its growth profile and expects the multiple to expand with continued.
- 07/13/2022
|
AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q4 2022 Results - Earnings Call Transcript
- AngioDynamics, Inc. (NASDAQ:ANGO ) Q4 2022 Earnings Conference Call July 12, 2022 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James William Plovanic - Canaccord Matthew Mishan - KeyBanc Capital Markets Operator Good morning, and welcome to AngioDynamics' Fourth Quarter and Fiscal Year 2022 Earnings Call. At this time, all participants are in a listen-only mode.
- 07/12/2022
|
AngioDynamics (ANGO) Q4 Earnings Match Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/12/2022
|
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
- AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.
- 06/28/2022
|
AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that it will report financial results for the fourth quarter and fiscal year 2022 before the market open on Tuesday, July 12, 2022. The Company's management will host a conference call at 8:00 a.m. ET the same
- 06/15/2022
|
AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag
- AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.
- 04/08/2022
|
Why AngioDynamics Stock Soared 10% Today
- AngioDynamics "beat earnings" in Q3 -- but what does that really mean?
- 04/07/2022
|
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2022 Results - Earnings Call Transcript
- AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2022 Results - Earnings Call Transcript
- 04/07/2022
|
AngioDynamics Posts Wider Q3 Loss On Higher Costs, Reaffirms FY22 Outlook
- AngioDynamics Inc (NASDAQ: ANGO) has reported a Q3 FY22 adjusted EPS of $0.03, ahead of the consensus of $(0.01), and better than the consensus of $0.02 reported a year ago. Q3 sales increased 3.9% Y/Y to $73.97 million, missing the analyst consensus of $76.32 million.
- 04/07/2022
|
New Strong Sell Stocks for March 8th
- ANGO, BURL, and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on March 8, 2022.
- 03/08/2022
|
Is This Small-Cap Medical Devices Stock a Buy?
- AngioDynamics managed to deliver solid revenue growth in the second quarter despite COVID-19 headwinds.
- 02/01/2022
|
AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top
- AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.
- 01/07/2022
|
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2022 Results - Earnings Call Transcript
- AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2022 Results - Earnings Call Transcript
- 01/06/2022
|
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
- AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 12/30/2021
|
AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market open on Thursday, January 6, 2022. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial
- 12/15/2021
|
Is This Under-the-Radar Medical Devices Stock a Buy?
- The medical devices company beat analyst expectations in the first quarter of its new fiscal year. Could it be a buy?
- 11/03/2021
|
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
- AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.
- 10/01/2021
|
Investors Cheer AngioDynamics' Q1 Beat, Raised FY22 Sales Outlook
- AngioDynamics Inc (NASDAQ: ANGO) reported a Q1 FY22 adjusted EPS loss of $(0.02), ahead of the consensus of $(0.04). Q1 sales increased 9.6% Y/Y to $77 million, beating the analyst consensus of $71.31 million.
- 09/30/2021
|
AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q1 2022 Results - Earnings Call Transcript
- AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q1 2022 Results - Earnings Call Transcript
- 09/30/2021
|
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the first quarter of fiscal year 2022, which ended August 31, 2021. “We had a solid first quarter, and our team continues to deliver strong revenue performance and invest in our growth drivers while advancing our ongoing transformation,” commented Jim Clemmer,
- 09/30/2021
|
AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market open on Thursday, September 30, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, di
- 09/15/2021
|
Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?
- AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
- 08/12/2021
|
After Beating Estimates, Is This Little-Known Medical Device Company a Buy?
- AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?
- 07/18/2021
|
AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top
- AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.
- 07/14/2021
|
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2021 Results - Earnings Call Transcript
- AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2021 Results - Earnings Call Transcript
- 07/13/2021
|
AngioDynamics Breaks-Even In FY21, Issues Mixed Forecasts For FY22
- AngioDynamics Inc (NASDAQ: ANGO) reports break-even in 4Q of 2021 with adjusted EPS of $0.00, a turnaround from EPS of (0.06) posted a year ago. The Company witnessed the pressure from COVID-19 gradually alleviate over the year, and business is now trending close to normalized run rates.
- 07/13/2021
|
AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will host its Investor & Technology Day on Tuesday, July 13, from 9:30 a.m. to approximately 11:30 a.m. ET, which will include a question-and-answer session. The event, to be held virtually, will include presentations from AngioDynamics' executive leadership team. The Co
- 07/08/2021
|
AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market open on Tuesday, July 13, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1
- 06/24/2021
|
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
- AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
- 06/22/2021
|
AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System
- AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.
- 06/09/2021
|
AngioDynamics (ANGO) Up 4.3% Since Last Earnings Report: Can It Continue?
- AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
- 04/29/2021
|
AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it submitted a 510(k) application to the United States Food and Drug Administration (FDA) for the AlphaVac System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the venous syst
- 04/12/2021
|
AngioDynamics to Present at the Needham Virtual Healthcare Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Needham Virtual Healthcare Conference at 8:45 a.m. ET on Monday, April 12, 2021. A live webcast of the presentation will be acces
- 04/05/2021
|
AngioDynamics (ANGO) Q3 Earnings and Revenues Top Estimates
- AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.
- 03/31/2021
|
AngioDynamics (ANGO) Soars 7.9%: Is Further Upside Left in the Stock?
- AngioDynamics (ANGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 03/31/2021
|
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2021 Results - Earnings Call Transcript
- AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2021 Results - Earnings Call Transcript
- 03/30/2021
|
AngioDynamics (ANGO) Surpasses Q3 Earnings and Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of 166.67% and 4.04%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2021
|
ANGO Stock Price Increased Over 10% Pre-Market: Why It Happened
- The stock price of AngioDynamics, Inc. (NASDAQ: ANGO) increased by over 10% pre-market. This is why it happened.
- 03/30/2021
|
Recap: AngioDynamics Q3 Earnings
- Shares of AngioDynamics (NASDAQ:ANGO) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 100.00% year over year to $0.02, which beat the estimate of ($0.02).
- 03/30/2021
|
A Preview Of AngioDynamics's Earnings
- AngioDynamics (NASDAQ:ANGO) unveils its next round of earnings this Tuesday, March 30. Here is Benzinga's everything-that-matters guide for the earnings announcement.
- 03/29/2021
|
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
- AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/23/2021
|
AngioDynamics (ANGO) at a 52-Week High: What's Driving It?
- AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.
- 03/10/2021
|
AngioDynamics to Present at the Barclays Virtual Global Healthcare Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Barclays Virtual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 9, 2021. A live webcast of the presentation will
- 03/01/2021
|
Why Is AngioDynamics (ANGO) Up 8.7% Since Last Earnings Report?
- AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
- 02/06/2021
|
Grab These 4 Breakout Stocks for Spectacular Gains
- In case a stock falls below the lower bound of this band, it may be time to offload it from your portfolio.
- 02/04/2021
|
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
- Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.
- 02/02/2021
|
AngioDynamics' (ANGO) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in AngioDynamics (ANGO).
- 01/29/2021
|
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
- Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/15/2021
|
Today's Stock Market News & Events: 1/11/2021
- The Dow finished the first trading Friday of 2021 at an all-time closing high, despite a disappointing jobs report being released for December.
- 01/11/2021
|
AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates
- AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.
- 01/08/2021
|
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2021 Results - Earnings Call Transcript
- AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2021 Results - Earnings Call Transcript
- 01/07/2021
|
AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
- 01/07/2021
|
AngioDynamics to Present at the J.P. Morgan Virtual Healthcare Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 2:50 p.m. ET on Thursday, January 14, 2021. A live webcast of the prese
- 01/04/2021
|
AngioDynamics to Present at the Needham Virtual Growth Conference
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 23rd Annual Needham Virtual Growth Conference at 1:15 p.m. ET on Monday, January 11, 2021. A live webcast of the presentation wi
- 12/29/2020
|
AngioDynamics to Report Fiscal 2021 Second Quarter Financial Results on January 7, 2021
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2021 before the market open on Thursday, January 7, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial
- 12/09/2020
|
Assenagon Asset Management S.A. Buys 140,286 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)
- Assenagon Asset Management S.A. lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 26.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 666,586 shares of the medical instruments supplier’s stock after purchasing an additional 140,286 shares during the quarter. Assenagon Asset Management […]
- 10/09/2020
|
Lackluster Growth And Margins Remain Major Issues For AngioDynamics (NASDAQ:ANGO)
- Declines in procedure counts have increased the pressures on AngioDynamics' business, but weak core growth is a long-standing issue, as is weak margin leverage.
- 10/07/2020
|
AQR Capital Management LLC Has $728,000 Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)
- AQR Capital Management LLC lifted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 12.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 71,566 shares of the medical instruments supplier’s stock after acquiring an additional 7,890 shares during the period. AQR […]
- 10/02/2020
|
De netto omzet van AngioDynamics steeg met 6,3% in Q1 | Invezz
- De netto omzet van AngioDynamics steeg met 6,3% in Q1. Het bedrijf verwacht een jaarlijkse netto omzet van £215,97 tot £220,63 miljoen.
- 09/29/2020
|
Le vendite nette di AngioDynamics sono aumentate nel Q1 | Invezz
- L'azienda si aspetta da £215,97 a £220,63 milioni di vendite nette annuali. AngioDynamics valuta la sua liquidità e gli equivalenti a £37,21 milioni.
- 09/29/2020
|
AngioDynamics’ net sales jump 6.3% in the fiscal first quarter.
- AngioDynamics’ net sales jump 6.3% in the fiscal first quarter. The company expects £215.97 to £220.63 million of annual net sales.
- 09/29/2020
|
AngioDynamics Reports Fiscal 2021 First Quarter Financial Results
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular dise
- 09/29/2020
|
AngioDynamics Announces Commercial Launch of Auryon Atherectomy System in United States
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular dise
- 09/21/2020
|
Global Central Venous Catheter Market to Surpass US$ 3,060.3 Million by 2027, Says Coherent Market Insights (CMI)
- The global central venous catheter market will rise during the forecast period due to new product launches and product approvals.
- 09/17/2020
|
AngioDynamics Announces First Patient Enrolled in PATHFINDER I Registry Examining Long-Term Effectiveness and Safety of Auryon Atherectomy System
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the enrollment of the first patient in the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05).
- 08/17/2020
|
Why Is AngioDynamics (ANGO) Down 1.3% Since Last Earnings Report?
- AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 08/15/2020
|
New Strong Sell Stocks for August 5th
- Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- 08/05/2020
|
AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will participate in a virtual fireside chat at the 40th Annual Canaccord Genuity Growth Conference at 1:30 p.m. ET on Wednesday, August 12, 2020.
- 08/03/2020
|
AngioDynamics to Participate in a Virtual Fireside Chat at the Canaccord Genuity Growth Conference
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular dise
- 08/03/2020
|
Acutus Medical Files For IPO For Commercialization Push
- Acutus Medical has filed to raise $75 million in a U.S. IPO, although the final figure may differ.
- 07/23/2020
|
AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates
- AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.
- 07/17/2020
|
AngioDynamics, Inc. (ANGO) Q4 2020 Earnings Call Transcript | AlphaStreet
- AngioDynamics, Inc. (NASDAQ: ANGO) Q4 2020 earnings call dated July 16, 2020 Corporate Participants: Jim Clemmer -- President and Chief Executive Officer Stephen A. Trowbridge -- Executive Vice Presid
- 07/16/2020
|
Edited Transcript of ANGO earnings conference call or presentation 16-Jul-20 12:00pm GMT
- Q4 2020 AngioDynamics Inc Earnings Call
- 07/16/2020
|
AngioDynamics Inc (ANGO) Q4 2020 Earnings Call Transcript
- The news release detailing the fourth quarter and fiscal year 2020 results crossed the wire earlier this morning and is available on the Company's website. This conference call is also being broadcast live over the Internet at the Investors section of the Company's website at www.angiodynamics.com. Before we begin, I would like to caution listeners that during the course of this conference call, the Company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margins for fiscal year 2021.
- 07/16/2020
|
AngioDynamics' (ANGO) CEO Jim Clemmer on Q4 2020 Results - Earnings Call Transcript
- AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2020 Earnings Conference Call July 16, 2020 8:00 AM ET Company Participants Jim Clemmer – President and Chief Executive Officer Steve Trowbridge – Executive Vice President and Chief Financial Officer Conference Call Participants Cecilia Furlong – Canaccord Genuity Matthew Mishan – KeyBanc Matt Wizman – Raymond James Presentation Operator Good morning, and welcome to the AngioDynamics Fourth Quarter and Fiscal Year 2020 Earnings Call.
- 07/16/2020
|
AngioDynamics (ANGO) Reports Q4 Loss, Lags Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of -20.00% and -6.28%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/16/2020
|
Key highlights from AngioDynamics (ANGO) Q4 2020 earnings results | AlphaStreet
- AngioDynamics, Inc. (NASDAQ: ANGO) today announced its fourth quarter financial results for the period ended May 31, 2020. Net loss for the fourth quarter was $156 million, or $4.10 per share, compare
- 07/16/2020
|
AngioDynamics: Q4 Earnings Insights
- Shares of AngioDynamics (NASDAQ:ANGO) were unchanged after the company reported Q4 results.Quarterly Results Earnings per share fell 124.00% over the past year to ($0.06), which were in line with the estimate of ($0.06).Revenue of $58,332,000 declined by 39.43% year over year, which missed the estimate of $64,300,000.Outlook Earnings guidance hasn't been issued by the company for now.AngioDynamics hasn't issued any revenue guidance for the time being.Details Of The Call Date: Jul 16, 2020View more earnings on ANGOTime: 08:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/hq97nqzrRecent Stock Performance Company's 52-week high was at $21.90Company's 52-week low was at $7.48Price action over last quarter: Up 7.39%Company Profile AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.See more from Benzinga * Earnings Scheduled For July 16, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/16/2020
|
AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the fourth quarter of fiscal year 2020, which ended May 31, 2020.
- 07/16/2020
|
AngioDynamics, Inc. 2020 Q4 - Results - Earnings Call Presentation
- The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2020 Q4 earnings call..
- 07/16/2020
|
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
- AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/09/2020
|
AngioDynamics (NASDAQ:ANGO) Share Prices Have Dropped 52% In The Last Year
- Even the best stock pickers will make plenty of bad investments. And unfortunately for AngioDynamics, Inc...
- 07/08/2020
|
Global Lung Cancer Surgery Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com
|
Hedge Funds Never Been Less Bullish On AngioDynamics, Inc. (ANGO)
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/04/2020
|
Global Electrosurgery Devices Market By Product, By Application, By End-user, By Region, Forecast & Opportunities, 2025
- This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Electrosurgery Devices Market By Product (Electrosurgical Generators (Radiofrequency, Ultrasonic, Argon Plasma, Cryoablation, Microwave, Combination and Smoke Evacuators), Electrosurgical Instruments (Electrosurgical Electrodes (Monopolar, Bipolar), Pencils (Monopolar, Bipolar), Forceps, Cryoprobes, Nano knifes and Others)), Accessories), By Application (Orthopedics, Oncology, Cardiovascular, General, Cosmetic, Neurology and Others), By End-user (Hospitals, Ambulatory Surgical Centers and Others), By Region, Forecast & Opportunities, 2025
- 06/30/2020
|
AngioDynamics to Report Fiscal 2020 Fourth Quarter and Full-Year Financial Results on July 16, 2020
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2020 before the market open on Thursday, July 16, 2020. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.
- 06/23/2020
|
AngioDynamics to Report Fiscal 2020 Fourth Quarter and Full-Year Financial Results on July 16, 2020
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular dise
- 06/23/2020
|
Massachusetts Financial Services Co. MA Purchases 17,947 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)
- Massachusetts Financial Services Co. MA increased its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 18.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,395 shares of the medical instruments supplier’s stock after purchasing an additional 17,947 shares during the period. […]
- 06/18/2020
|
Buy These 5 Low Leverage Stocks to Avoid Debt-Related Risk
- Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.
- 06/17/2020
|
Global Intravenous (IV) Therapy and Vein Access Market Insights, 2017 to 2028 - ResearchAndMarkets.com
|
Here's Why You Should Add AngioDynamics to Your Portfolio
- AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.
- 06/15/2020
|
Catheter Market Size is Projected to Witness 8.8% CAGR in Near Future: P&S Intelligence
- Around the world, the volume of interventional radiology procedures is rising, on account of being less invasive than conventional, open medical procedures,
- 06/15/2020
|
AngioDynamics (NASDAQ:ANGO) Stock Rating Lowered by BidaskClub
- AngioDynamics (NASDAQ:ANGO) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, BidAskClub reports. A number of other equities research analysts have also recently issued reports on the company. ValuEngine cut AngioDynamics from a “strong-buy” rating to a “buy” rating in a […]
- 06/15/2020
|
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
- YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery...
- 06/15/2020
|
AngioDynamics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the Raymond James Human Health Innovation Conference at 12:20 p.m. ET on Thursday, June 18, 2020.
- 06/08/2020
|
Global Centesis Catheters Market by Type, Procedure, Application, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com
|
Medical Rubber and Balloon Product Market Analysis as per the Latest COVID-19 Impact
- Jun 01, 2020 (Heraldkeepers) --
New York, June 1, 2020:You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 06/01/2020
|
Amid the COVID-19 crisis and the looming economic recession, the Medical Laser Systems market worldwide will grow by a projected US$3.1 Billion, during the analysis period
- NEW YORK, May 25, 2020 /PRNewswire via COMTEX/ --
NEW YORK, May 25, 2020 /PRNewswire/ -- Amid the COVID-19 crisis and the looming economic recession, the...
- 05/25/2020
|
Impact Of COVID-19 On Spider Vein Removal Treatment Market Outlook 2025, Size, Forecasts, Demand, Competitive Analysis, Growth Factors, Key Players
- May 18, 2020 (AmericaNewsHour) -- Kenneth Research has published a detailed report on Spider Vein Removal Treatment Market which has been categorized by...
- 05/19/2020
|
Angiography Devices Market Size, Trends | Forecast 2020-2027
- May 11, 2020 (Market Prediction via COMTEX) --
As per the research held by Acumen Research and Consulting, "the global Angiography Devices market anticipated...
- 05/11/2020
|
AngioDynamics to Present at the UBS Virtual Global Healthcare Conference
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 9:10 a.m. ET on Monday, May 18, 2020.
- 05/07/2020
|
AngioDynamics (ANGO) Down 1.6% Since Last Earnings Report: Can It Rebound?
- AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 05/07/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 12.1% in April
- AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 959,600 shares, an increase of 12.1% from the March 31st total of 855,900 shares. Based on an average daily trading volume, of 305,500 shares, the short-interest ratio is […]
- 05/02/2020
|
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
- Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
- 04/27/2020
|
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
- Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
- 04/27/2020
|
Avanos Medical (AVNS) Receives a Buy from KeyBanc
- In a report released today, Matthew Mishan from KeyBanc maintained a Buy rating on Avanos Medical (AVNS), with a price target of $45.00. The company's
- 04/27/2020
|
Avanos Medical (AVNS) Receives a Buy from KeyBanc
- In a report released today, Matthew Mishan from KeyBanc maintained a Buy rating on Avanos Medical (AVNS – Research Report),
- 04/27/2020
|
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
|
AngioDynamics (NASDAQ:ANGO) Rating Increased to Sell at BidaskClub
- AngioDynamics (NASDAQ:ANGO) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Saturday, BidAskClub reports. Other equities analysts also recently issued research reports about the stock. ValuEngine downgraded shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a research note on […]
- 04/25/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Stock Position Raised by Bank of America Corp DE
- Bank of America Corp DE raised its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 17.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,781 shares of the medical instruments supplier’s stock after purchasing an additional 9,675 shares during the period. […]
- 04/24/2020
|
Ablation Devices Market Poised for Stellar Growth Through 2029; COVID-19 Outbreak Briefly Derails the Market: Future Market Insights
- Leading innovators in the global ablation devices market must channel their resources towards research and development, and product launches in order to maintain their hegemony. DUBAI, UAE / ACCESSWIRE ...
- 04/22/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update
- AngioDynamics, Inc. (NASDAQ:ANGO) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 855,900 shares, a drop of 5.2% from the March 15th total of 902,900 shares. Based on an average trading volume of 332,400 shares, the short-interest ratio is currently 2.6 days. Approximately […]
- 04/22/2020
|
First Citizens Bank & Trust Co. Purchases Shares of 11,326 AngioDynamics, Inc. (NASDAQ:ANGO)
- First Citizens Bank & Trust Co. purchased a new stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 11,326 shares of the medical instruments supplier’s stock, valued at approximately $118,000. A number of other large investors […]
- 04/21/2020
|
Medical Laser Systems Market to Show Massive Growth Due to Rising Acceptance of Advanced Laser-based Treatments Till 2022 | Million Insights
- Global Medical Laser Systems Market is anticipated to reach USD 12.5 billion by 2022. Medical lasers are mainly used for the treatment and diagnosis of medical circumstances and are subject to photochemical, photoablation and photothermal reaction. The factors that propel the growth of the Medical Laser
- 04/21/2020
|
Assenagon Asset Management S.A. Sells 12,005 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)
- Assenagon Asset Management S.A. decreased its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 4.2% in the 1st quarter, Holdings Channel.com reports. The firm owned 272,957 shares of the medical instruments supplier’s stock after selling 12,005 shares during the quarter. Assenagon Asset Management S.A.’s holdings in AngioDynamics were worth $2,847,000 as of its most recent […]
- 04/21/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Stake Lifted by Nuveen Asset Management LLC
- Nuveen Asset Management LLC increased its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 105.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 541,551 shares of the medical instruments supplier’s stock after buying an additional 278,403 shares during the […]
- 04/19/2020
|
Zacks: Brokerages Anticipate AngioDynamics, Inc. (NASDAQ:ANGO) Will Post Earnings of -$0.05 Per Share
- Wall Street analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report earnings per share of ($0.05) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for AngioDynamics’ earnings. The lowest EPS estimate is ($0.09) and the highest is $0.00. AngioDynamics reported earnings per share of $0.25 in the same quarter last year, […]
- 04/19/2020
|
25,795 Shares in AngioDynamics, Inc. (NASDAQ:ANGO) Acquired by 6 Meridian
- 6 Meridian purchased a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 25,795 shares of the medical instruments supplier’s stock, valued at approximately $269,000. 6 Meridian owned about 0.07% of AngioDynamics as of its most […]
- 04/18/2020
|
Alliancebernstein L.P. Sells 35,770 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)
- Alliancebernstein L.P. reduced its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 39.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 55,200 shares of the medical instruments supplier’s stock after selling 35,770 shares during the quarter. Alliancebernstein L.P. owned 0.15% of […]
- 04/18/2020
|
AngioDynamics (NASDAQ:ANGO) Downgraded by BidaskClub to "Strong Sell"
- AngioDynamics (NASDAQ:ANGO) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday, BidAskClub reports. A number of other research firms have also weighed in on ANGO. ValuEngine lowered shares of AngioDynamics from a “strong-buy” rating to a “buy” rating in a […]
- 04/17/2020
|
The central intravenous catheters market is expected to grow at a CAGR of over 5% during the period 2019-2025
- With the Purchase of Global Central Intravenous Catheter Market Report,Receive a FREE Copy of Market Impact of COVID-19 on Businesses.Read the full report: https://www.reportlinker.com/p05882091/?utm_source=PRN The central intravenous catheters market is expected to grow at a CAGR of over 5% during the
- 04/15/2020
|
Bank of New York Mellon Corp Has $6.78 Million Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)
- Bank of New York Mellon Corp cut its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 2.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 423,327 shares of the medical instruments supplier’s stock after selling 9,336 shares during the quarter. Bank of New York Mellon Corp […]
- 04/14/2020
|
AngioDynamics slows spending as hospitals delay elective surgeries amid coronavirus
- "We have had great momentum heading into this, and we want to be sure we're ready to continue to build upon that momentum as we exit whenever that may be," said CEO Jim Clemmer.
- 04/13/2020
|
AngioDynamics (NASDAQ:ANGO) Given New $14.00 Price Target at Canaccord Genuity
- AngioDynamics (NASDAQ:ANGO) had its target price reduced by Canaccord Genuity from $18.00 to $14.00 in a report released on Wednesday morning, BenzingaRatingsTable reports. Canaccord Genuity currently has a hold rating on the medical instruments supplier’s stock. ANGO has been the subject of a number of other reports. BidaskClub upgraded shares of AngioDynamics from a strong […]
- 04/12/2020
|
FY2020 EPS Estimates for AngioDynamics, Inc. Lowered by KeyCorp (NASDAQ:ANGO)
- AngioDynamics, Inc. (NASDAQ:ANGO) – Investment analysts at KeyCorp reduced their FY2020 earnings estimates for shares of AngioDynamics in a research report issued to clients and investors on Tuesday, April 7th. KeyCorp analyst M. Mishan now expects that the medical instruments supplier will post earnings of $0.06 per share for the year, down from their previous […]
- 04/11/2020
|
Edited Transcript of ANGO earnings conference call or presentation 7-Apr-20 12:00pm GMT
- Q3 2020 AngioDynamics Inc Earnings Call
- 04/09/2020
|
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
- AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
- 04/09/2020
|
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
- AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
- 04/09/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Holdings Raised by AQR Capital Management LLC
- AQR Capital Management LLC lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,501 shares of the medical instruments supplier’s stock after purchasing an additional 1,086 shares during the quarter. […]
- 04/09/2020
|
65 Stocks Moving In Wednesday's Mid-Day Session
- Gainers
Moleculin Biotech Inc (NASDAQ: MBRX) shares climbed 174% to $1.54 after it said that independent research found 2-deoxy-D-glucose (2-DG)to reduce replication of...
- 04/08/2020
|
Canaccord Genuity Maintains Hold on AngioDynamics, Lowers Price Target to $14
|
's Top Upgrades, Downgrades For April 8, 2020
- Upgrades
Citigroup changed the rating for ANGI Homeservices Inc (NASDAQ: ANGI) from Neutral to Buy. ANGI Homeservices earned $0.00 in the fourth quarter, compared...
- 04/08/2020
|
Analysts Conflicted on These Healthcare Names: AngioDynamics (ANGO) and SAGE Therapeutics (SAGE)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AngioDynamics (ANGO) and SAGE Therapeutics (SAGE).
- 04/08/2020
|
Analysts Conflicted on These Healthcare Names: AngioDynamics (NASDAQ: ANGO) and SAGE Therapeutics (NASDAQ: SAGE)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AngioDynamics (ANGO –
- 04/08/2020
|
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc ANGO
- AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc KeyBanc ANGO
- 04/08/2020
|
Goldman Sachs Group Inc. Increases Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)
- Goldman Sachs Group Inc. increased its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 50.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 399,443 shares of the medical instruments supplier’s stock after buying an additional 133,243 shares during the […]
- 04/08/2020
|
KeyBanc Downgrades AngioDynamics to Sector Weight
|
AngioDynamics (ANGO) Q3 2020 Earnings Call Transcript
- ANGO earnings call for the period ending March 31, 2020.
- 04/08/2020
|
Edited Transcript of ANGO earnings conference call or presentation 7-Apr-20 12:00pm GMT
- Q3 2020 AngioDynamics Inc Earnings Call
- 04/07/2020
|
AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2020 Results - Earnings Call Transcript
- AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2020 Results Earnings Conference Call April 7, 2020 8:00 AM ET Company Participants Jim Clemmer - President & CEO Steve
- 04/07/2020
|
Recap: AngioDynamics Q3 Earnings
- Shares of AngioDynamics (NASDAQ:ANGO) jumped over 7% after the company reported upbeat Q3 results.Quarterly Results Earnings per share fell 94.74% year over year to $0.01, which beat the estimate of ($0.03).Revenue of $69,780,000 lower by 19.18% from the same period last year, which beat the estimate of $68,550,000.Looking Ahead AngioDynamics hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Apr 07, 2020View more earnings on ANGOTime: 10:03 PM ETWebcast URL: https://edge.media-server.com/mmc/p/cbupojapPrice Action Company's 52-week high was at $23.61Company's 52-week low was at $7.48Price action over last quarter: down 28.94%Company Description AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.See more from Benzinga * Greenbrier Companies: Q2 Earnings Insights * Lindsay: Q2 Earnings Insights * 12 Energy Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 04/07/2020
|
Fly Intel: Pre-market Movers XOM;M;W;HOLX;NGM;GBX;ANGO;LNN;SEAC
- Fly Intel: Pre-market Movers XOM M W HOLX NGM GBX ANGO LNN SEAC
- 04/07/2020
|
AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc ANGO
- AngioDynamics downgraded to Sector Weight from Overweight at KeyBanc KeyBanc ANGO
- 04/07/2020
|
AngioDynamics (ANGO) Beats Q3 Earnings and Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/07/2020
|
AngioDynamics (ANGO) Beats Q3 Earnings and Revenue Estimates
- AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
- 04/07/2020
|
The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) * Forty Seven Inc (NASDAQ: FTSV) * Masimo Corporation (NASDAQ: MASI) * Seattle Genetics, Inc. (NASDAQ: SGEN) * Vertex Pharmaceuticals Incorporated
- 04/07/2020
|
AngioDynamics withdraws FY20 guidance due to COVID-19 ANGO
- AngioDynamics withdraws FY20 guidance due to COVID-19 ANGO
- 04/07/2020
|
AngioDynamics reports Q3 adj. EPS 1c, consensus (3c) ANGO
- AngioDynamics reports Q3 adj. EPS 1c, consensus (3c) ANGO
- 04/07/2020
|
AngioDynamics Q3 EPS $0.01 Beats $(0.03) Estimate, Sales $69.78M Beat $68.55M Estimate
|
AngioDynamics: Fiscal 3Q Earnings Snapshot
- LATHAM, N.Y. (AP) _ AngioDynamics Inc. (ANGO) on Tuesday reported a fiscal third-quarter loss of $5.7 million, after reporting a profit in the same period a year earlier. The Latham, New York-based company said it had a loss of 15 cents per share. Earnings, adjusted for one-time gains and costs, were 1 cent per share. The medical device maker posted revenue of $69.8 million in the period. AngioDynamics shares have dropped 36% since the beginning of the year. The stock has dropped 55% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ANGO at https://www.zacks.com/ap/ANGO
- 04/07/2020
|
BRIEF-Angiodynamics Reports Q3 Adj. Earnings Per Share $0.01
- AngioDynamics Inc:
- 04/07/2020
|
AngioDynamics: Fiscal 3Q Earnings Snapshot
- LATHAM, N.Y. (AP) _ AngioDynamics Inc. (ANGO) on Tuesday reported a fiscal third-quarter loss of $5.7 million, after reporting a profit in the same period a year earlier.
The Latham, New York-based company said it had a loss of 15 cents per share. Ea
- 04/07/2020
|
AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the third quarter of fiscal year 2020, which ended February 29, 2020.
- 04/07/2020
|
AngioDynamics, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / April 7, 2020 / AngioDynamics, Inc. (NASDAQ:ANGO) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on April 7, 2020 at 8:00 AM ...
- 04/07/2020
|
Earnings Scheduled For April 7, 2020
- Companies Reporting Before The Bell
The Greenbrier Companies, Inc. (NYSE: GBX) is projected to report quarterly earnings at $0.29 per share on revenue of $798.97 million....
- 04/07/2020
|
Advisor Group Inc. Reduces Position in AngioDynamics, Inc. (NASDAQ:ANGO)
- Advisor Group Inc. cut its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 26.8% during the fourth quarter, HoldingsChannel reports. The firm owned 2,945 shares of the medical instruments supplier’s stock after selling 1,076 shares during the quarter. Advisor Group Inc.’s holdings in AngioDynamics were worth $48,000 as of its most recent SEC filing. Other large investors […]
- 04/07/2020
|
AngioDynamics Q3 2020 Earnings Preview
- AngioDynamics (NASDAQ:ANGO) is scheduled to announce Q3 earnings results on Tuesday, April 7th, before market open.The consensus EPS Estimate is -$0.03 (-115.8% Y/Y) and the consensus Revenue Estimate
- 04/06/2020
|
AngioDynamics (NASDAQ: ANGO) Q2 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of AngioDynamics Inc. - ANGO stock
- 04/06/2020
|
Insights on the Global Tumor Ablation Industry to 2027 - Drivers, Restraints, Opportunities & Threats - ResearchAndMarkets.com
- The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
- 04/06/2020
|
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
- Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts...
- 04/05/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Shares Bought by Connor Clark & Lunn Investment Management Ltd.
- Connor Clark & Lunn Investment Management Ltd. raised its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 26.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 147,313 shares of the medical instruments supplier’s stock after purchasing an additional 31,270 shares during the quarter. Connor Clark & […]
- 04/04/2020
|
Brinker Capital Inc. Sells 5,846 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)
- Brinker Capital Inc. cut its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 23.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,475 shares of the medical instruments supplier’s stock after selling 5,846 shares during the quarter. Brinker Capital Inc. owned approximately 0.05% […]
- 04/04/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Shares Acquired by Cubist Systematic Strategies LLC
- Cubist Systematic Strategies LLC increased its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 484.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 82,654 shares of the medical instruments supplier’s stock after purchasing an additional 68,507 shares during the period. Cubist […]
- 04/03/2020
|
Global Tumor Ablation Market Outlook (2018 to 2027) - Agreements, Partnerships, Collaborations and Joint Ventures
- Dublin, April 02, 2020 -- The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The Global.
- 04/02/2020
|
AngioDynamics (NASDAQ:ANGO) Cut to Buy at ValuEngine
- AngioDynamics (NASDAQ:ANGO) was downgraded by investment analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday, ValuEngine reports. Separately, BidaskClub upgraded AngioDynamics from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 24th. One analyst has rated the stock with […]
- 04/02/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO): Are Analysts Optimistic?
- AngioDynamics, Inc.'s (NASDAQ:ANGO): AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical...
- 04/01/2020
|
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
- AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/31/2020
|
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
- AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/31/2020
|
AngioDynamics (ANGO) Set to Announce Earnings on Tuesday
- AngioDynamics (NASDAQ:ANGO) will be posting its quarterly earnings results before the market opens on Tuesday, April 7th. Analysts expect AngioDynamics to post earnings of ($0.03) per share for the quarter. AngioDynamics has set its FY 2020 Pre-Market guidance at 0.10-0.15 EPS and its FY20 guidance at $0.10-0.15 EPS.Parties interested in participating in the company’s conference […]
- 03/31/2020
|
Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline
|
Laser Fiber In Medical Market Outlook 2025: Market Trends, Segmentation, Market Growth and Competitive Landscape
- Mar 30, 2020 (The Expresswire) --
Global “Laser Fiber In Medical Market” The report entitled “Global Laser Fiber In Medical Market Status and Future Forecast...
- 03/30/2020
|
Brokerages Anticipate AngioDynamics, Inc. (NASDAQ:ANGO) Will Post Quarterly Sales of $68.43 Million
- Wall Street brokerages expect AngioDynamics, Inc. (NASDAQ:ANGO) to report sales of $68.43 million for the current quarter, Zacks reports. Two analysts have provided estimates for AngioDynamics’ earnings, with estimates ranging from $68.05 million to $68.80 million. AngioDynamics posted sales of $86.34 million in the same quarter last year, which would indicate a negative year-over-year growth […]
- 03/29/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Sees Large Drop in Short Interest
- AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a large decline in short interest during the month of March. As of March 13th, there was short interest totalling 902,900 shares, a decline of 22.2% from the February 27th total of 1,160,000 shares. Based on an average trading volume of 277,400 shares, the short-interest ratio is presently […]
- 03/27/2020
|
-$0.03 EPS Expected for AngioDynamics, Inc. (NASDAQ:ANGO) This Quarter
- Equities research analysts expect that AngioDynamics, Inc. (NASDAQ:ANGO) will post earnings per share of ($0.03) for the current quarter, Zacks reports. Two analysts have issued estimates for AngioDynamics’ earnings. AngioDynamics posted earnings of $0.19 per share in the same quarter last year, which suggests a negative year over year growth rate of 115.8%. The firm […]
- 03/27/2020
|
Microcatheters Market Key Players, Regions, Manufacturers Analysis, Application and Specification, Cost Analysis, Price and Gross Margin by 2024
- Mar 26, 2020 (The Expresswire) --
"Final Report will add the analysis of the impact of COVID-19 on this industry" The report begins with a market overview...
- 03/26/2020
|
Electroporator Market: Top Key Manufacture, Analysis, Size, Share, Growth, Application, Region and Forecast 2020 to 2024
- Mar 26, 2020 (The Expresswire) --
"Final Report will add the analysis of the impact of COVID-19 on this industry" The report begins with a market overview...
- 03/26/2020
|
AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know
- AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/25/2020
|
AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know
- AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- 03/25/2020
|
AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know
|
Interventional Oncology Global Market - Forecast to 2026
- Interventional Oncology (IO) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, and other cancers.
- 03/24/2020
|
Worldwide Tumor Ablation Industry Insights, 2020: Dominated by Medtronic and Johnson & Johnson
- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to ResearchAndMarkets.com's offering.
- 03/24/2020
|
Panagora Asset Management Inc. Trims Stake in AngioDynamics, Inc. (NASDAQ:ANGO)
- Panagora Asset Management Inc. trimmed its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 49.5% in the 4th quarter, HoldingsChannel reports. The firm owned 5,996 shares of the medical instruments supplier’s stock after selling 5,882 shares during the period. Panagora Asset Management Inc.’s holdings in AngioDynamics were worth $96,000 as of its most recent filing with the […]
- 03/24/2020
|
Great West Life Assurance Co. Can Invests $721,000 in AngioDynamics, Inc. (NASDAQ:ANGO)
- Great West Life Assurance Co. Can purchased a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 45,499 shares of the medical instruments supplier’s stock, valued at approximately $721,000. Great West Life Assurance Co. Can owned […]
- 03/24/2020
|
AngioDynamics (NASDAQ:ANGO) Stock Rating Upgraded by BidaskClub
- AngioDynamics (NASDAQ:ANGO) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Tuesday, BidAskClub reports. Separately, ValuEngine upgraded AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. One investment analyst has rated the stock […]
- 03/24/2020
|
Peripheral Interventions Market demand to hit USD 11.5 bn by 2026: Global Market Insights, Inc.
- Selbyville, Delaware, March 23, 2020 -- Global Market Insights, Inc. has recently added a new report on peripheral interventions market which estimates the global market.
- 03/23/2020
|
Is AngioDynamics, Inc. (NASDAQ:ANGO) Potentially Undervalued?
- AngioDynamics, Inc. (NASDAQ:ANGO), which is in the medical equipment business, and is based in United States, received...
- 03/21/2020
|
North America's Tumor Ablation Market by Treatment, Technology, Application and Country - Forecast to 2025
- The "North America Tumor Ablation Market, by Treatment, by Technology, by Application, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
- 03/20/2020
|
The Global Tumor Ablation Market size is expected to reach $1.7 billion by 2025, rising at a market growth of 10.9% CAGR during the forecast period
- New York, March 20, 2020 -- Reportlinker.com announces the release of the report "Global Tumor Ablation Market By Treatment By Technology By Application By Region, Industry.
- 03/20/2020
|
Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region
- Dublin, March 20, 2020 -- The "Global Tumor Ablation Market Report 2020: Analysis by Treatment, Technology, Application and Region" report has been added to.
- 03/20/2020
|
Digest A Stepping Up in Volatility: ABB Ltd (ABB), AngioDynamics, Inc.(ANGO) , Evergy, Inc.(EVRG) | Post Analyst
- Shares of AngioDynamics, Inc. (ANGO) have traded between $7.49 – 25.48. The next earnings date is set for Apr 07, 2020. Let’s see how its prospects are shaping up. What does AngioDynamics, Inc.(ANGO) do? AngioDynamics, Inc. engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. …
- 03/19/2020
|
North American Tumor Ablation Market Analysis & Forecast, 2019-2025
- Dublin, March 19, 2020 -- The "North America Tumor Ablation Market, by Treatment, by Technology, by Application, by Country, Industry Analysis and Forecast, 2019 - 2025".
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
Contrasting United American Healthcare (OTCMKTS:UAHC) & AngioDynamics (OTCMKTS:ANGO)
- United American Healthcare (OTCMKTS:UAHC) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations. Profitability This table compares United American Healthcare and AngioDynamics’ net margins, return on equity and […]
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
AngioDynamics (NASDAQ:ANGO) Downgraded by BidaskClub
- AngioDynamics (NASDAQ:ANGO) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Tuesday, BidAskClub reports. Separately, ValuEngine upgraded AngioDynamics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with […]
- 03/17/2020
|
Charles Schwab Investment Management Inc. Increases Stake in AngioDynamics, Inc. (NASDAQ:ANGO)
- Charles Schwab Investment Management Inc. raised its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 1.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,826 shares of the medical instruments supplier’s stock after buying an additional 4,294 shares […]
- 03/16/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update
- AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 1,160,000 shares, an increase of 12.6% from the February 13th total of 1,030,000 shares. Based on an average trading volume of 314,800 shares, the short-interest ratio is currently 3.7 days. Approximately […]
- 03/15/2020
|
Stocks To Watch: 0% To The Rescue?
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 03/14/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
- 03/11/2020
|
Barclays PLC Grows Position in AngioDynamics, Inc. (NASDAQ:ANGO)
- Barclays PLC boosted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 46.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 66,410 shares of the medical instruments supplier’s stock after purchasing an additional 20,930 shares during the period. Barclays PLC’s holdings […]
- 03/11/2020
|
AngioDynamics to Report Fiscal 2020 Third Quarter Financial Results on April 7, 2020
- LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2020 before the market open on Tuesday, April 7, 2020. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1-8
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
- 03/10/2020
|
AngioDynamics (NASDAQ:ANGO) Upgraded by BidaskClub to "Sell"
- AngioDynamics (NASDAQ:ANGO) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports. Separately, ValuEngine raised AngioDynamics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. One analyst has rated the stock with […]
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
Mackay Shields LLC Acquires 67,200 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)
- Mackay Shields LLC grew its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 129.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 119,300 shares of the medical instruments supplier’s stock after acquiring an additional 67,200 shares during the period. Mackay Shields LLC owned […]
- 03/08/2020
|
AngioDynamics, Inc. (NASDAQ:ANGO) Shares Purchased by Bank of Montreal Can
- Bank of Montreal Can increased its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 3,623.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 246,616 shares of the medical instruments supplier’s stock after purchasing an additional 239,993 shares during the quarter. […]
- 03/08/2020
|
New York State Common Retirement Fund Trims Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)
- New York State Common Retirement Fund lowered its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 54.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,400 shares of the medical instruments supplier’s stock after selling 39,500 shares during the period. New York State […]
- 03/08/2020
|
Stocks To Watch: Fading The Fear
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 03/07/2020
|
The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) Arcus Biosciences Inc (NYSE: RCUS ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Centogene NV (NASDAQ: CNTG ) Cue Biopharma Inc (NASDAQ: CUE ) Forty Seven Inc (NASDAQ: FTSV ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Molecular Templates Inc (NASDAQ: MTEM ) Natera Inc (NASDAQ: NTRA ) Ocular Therapeutix Inc (NASDAQ: OCUL ) (Piper Sandler lifted the price target for the shares from $7 to $11) Quest Diagnostics Inc (NYSE: DGX ) (announced plans to launch a COVID-19 test service) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 5.) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Aytu Bioscience Inc (NASDAQ: AYTU ) Celcuity Inc (NASDAQ: CELC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) Glaukos Corp (NYSE: GKOS ) Lantheus Holdings Inc (NASDAQ: LNTH ) Mylan NV (NASDAQ: MYL ) Neurometrix Inc (NASDAQ: NURO ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Orthofix Medical Inc (NASDAQ: OFIX ) Passage Bio Inc (NASDAQ: PASG ) (went public last week) Polarityte Inc (NASDAQ: PTE ) STRATA Skin Sciences Inc (NASDAQ: SSKN ) SurModics, Inc. (NASDAQ: SRDX ) (reacted to first-quarter results) T2 Biosystems Inc (NASDAQ: TTOO ) Xeris …
- 03/06/2020
|
Why AngioDynamics, Inc.’s (NASDAQ:ANGO) CEO Pay Matters To You
- In 2016 Jim Clemmer was appointed CEO of AngioDynamics, Inc. (NASDAQ:ANGO). This analysis aims first to contrast CEO...
- 03/06/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) 89bio Inc (NASDAQ: ETNB ) Arcus Biosciences Inc (NYSE: RCUS ) Arcturus Therapeutics Ltd (NASDAQ: ARCT )(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) Cue Biopharma Inc (NASDAQ: CUE ) IGM Biosciences Inc (NASDAQ: IGMS ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Ocular Therapeutix Inc (NASDAQ: OCUL )(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) Quest Diagnostics Inc (NYSE: DGX ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN )(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) Revolution Medicines Inc (NASDAQ: RVMD ) (IPOed mid-February) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX )(reacted to the company's fourth-quarter results) Syneos Health Inc (NASDAQ: SYNH ) Viela Bio Inc (NASDAQ: VIE ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AngioDynamics, Inc.
- 03/05/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
Global Urological Catheters Industry
- New York, March 04, 2020 -- Reportlinker.com announces the release of the report "Global Urological Catheters Industry" - https://www.reportlinker.com/p05151475/?utm_source=GNW.
- 03/04/2020
|
AngioDynamics (NASDAQ:ANGO) Raised to Strong-Buy at ValuEngine
- AngioDynamics (NASDAQ:ANGO) was upgraded by ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports. NASDAQ:ANGO opened at $11.75 on Tuesday. The business has a 50 day moving average of $13.51 and a 200 day moving average of $15.62. The company has a […]
- 03/03/2020
|
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
- 02/28/2020
|
Global Varicose Vein Treatment Market Is Expected to Reach USD 348.67 Million by 2025 : Fior Markets
- Newark, NJ, Feb. 28, 2020 -- As per the report published by Fior Markets, the global varicose vein treatment market is expected to grow from USD 231.05 Million in 2017 to USD.
- 02/28/2020
|
Stocks That Hit 52-Week Lows On Friday
|
AngioDynamics to Present at Two Investor Conferences in March
- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular dise
- 02/27/2020
|
